Rheumatoid arthritis prevention trials in individuals at risk of developing disease have shown variable efficacy, and the long-term outcomes of therapeutic disease interception remain uncertain. To address this gap, a study examined the long-term efficacy and safety of therapeutic intervention aimed at preventing rheumatoid arthritis, with particular emphasis on sustained disease prevention outcomes and treatment-related safety involving 143 participants. Over median follow-up duration of 55 months (IQR 23–74), during which the number of primary arthritis events increased from 54 to 119.
Although the magnitude of benefit declined over time, the initial between-group difference in restricted mean arthritis-free survival time observed at 2 years remained significant at 4 years, with abatacept demonstrating a 4.9-month improvement in arthritis-free survival compared with placebo. No…
